Chlamydia pneumoniae immunoreactivity in coronary artery plaques of patients with acute coronary syndromes and its relation with serology.

[1]  Christopher M O'Connor,et al.  Azithromycin for the secondary prevention of coronary heart disease events: the WIZARD study: a randomized controlled trial. , 2003, JAMA.

[2]  F. Crea,et al.  Antibody Response to Chlamydial Heat Shock Protein 60 Is Strongly Associated With Acute Coronary Syndromes , 2003, Circulation.

[3]  P. Shah,et al.  Effect of short-term treatment with azithromycin on recurrent ischaemic events in patients with acute coronary syndrome in the Azithromycin in Acute Coronary Syndrome (AZACS) trial: a randomised controlled trial , 2003, The Lancet.

[4]  J. Danesh,et al.  Chlamydia pneumoniae IgA titres and coronary heart disease; prospective study and meta-analysis. , 2002, European heart journal.

[5]  Peter Libby,et al.  Chlamydia pneumoniae as an emerging risk factor in cardiovascular disease. , 2002, JAMA.

[6]  P. Armstrong,et al.  Does chronic Chlamydia pneumoniae infection increase the risk of myocardial injury? Insights from patients with non-ST-elevation acute coronary syndromes. , 2002, American heart journal.

[7]  P. Roholl,et al.  The adventitia of atherosclerotic coronary arteries frequently contains Chlamydia pneumoniae. , 2001, Atherosclerosis.

[8]  P. Roholl,et al.  Distribution of Chlamydia pneumoniae in the Human Arterial System and Its Relation to the Local Amount of Atherosclerosis Within the Individual , 2001, Circulation.

[9]  N Rifai,et al.  High-sensitivity C-reactive protein: a novel and promising marker of coronary heart disease. , 2001, Clinical chemistry.

[10]  M. Sarvas,et al.  Chlamydia pneumoniae Proteins Induce Secretion of the 92-kDa Gelatinase by Human Monocyte– Derived Macrophages , 2001, Arteriosclerosis, thrombosis, and vascular biology.

[11]  B. Horne,et al.  Randomized Secondary Prevention Trial of Azithromycin in Patients With Coronary Artery Disease: Primary Clinical Results of the ACADEMIC Study , 2000, Circulation.

[12]  J. Danesh,et al.  Chlamydia pneumoniae IgG titres and coronary heart disease: prospective study and meta-analysis. , 2000, BMJ : British Medical Journal.

[13]  J. Mehta,et al.  Relationship of Chlamydia pneumoniae infection to severity of human coronary atherosclerosis. , 2000, Circulation.

[14]  J. Grayston.  Background and current knowledge of Chlamydia pneumoniae and atherosclerosis. , 2000, The Journal of infectious diseases.

[15]  H. Katus,et al.  Detection of Chlamydia pneumoniae within peripheral blood monocytes of patients with unstable angina or myocardial infarction. , 2000, The Journal of infectious diseases.

[16]  K. Shimada,et al.  High Prevalence of Seropositivity for Antibodies to Chlamydia-Specific Lipopolysaccharide in Patients with Acute Coronary Syndrome , 2000, Journal of cardiovascular risk.

[17]  D. Margolis,et al.  Chlamydiapneumoniae Inhibits Apoptosis in Human Peripheral Blood Mononuclear Cells Through Induction of IL-101 , 2000, The Journal of Immunology.

[18]  P. Apfalter,et al.  Isolation and Continuous Growth of Chlamydia pneumoniae from Arterectomy Specimens , 2000, European Journal of Clinical Microbiology and Infectious Diseases.

[19]  J. Ramires,et al.  Great amount of C.pneumoniae in ruptured plaque vessel segments at autopsy. A comparative study with stable plaques. , 2000, Arquivos brasileiros de cardiologia.

[20]  M. Netea,et al.  Acellular components of Chlamydia pneumoniae stimulate cytokine production in human blood mononuclear cells , 2000, European journal of immunology.

[21]  H. Margolis,et al.  Prevalence of antibody to hepatitis E virus among rodents in the United States. , 2000, The Journal of infectious diseases.

[22]  J. Gnarpe,et al.  Serological analysis of specific IgA to Chlamydia pneumoniae: increased sensitivity of IgA antibody detection using prolonged incubation and high antigen concentration , 2000, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[23]  G. Byrne,et al.  Chlamydia pneumoniae and atherosclerosis: links to the disease process. , 1999, American heart journal.

[24]  V. Tsang,et al.  Relation between direct detection of Chlamydia pneumoniae DNA in human coronary arteries at postmortem examination and histological severity (Stary grading) of associated atherosclerotic plaque. , 1999, Circulation.

[25]  D. Strachan,et al.  Relation of Chlamydia pneumoniae serology to mortality and incidence of ischaemic heart disease over 13 years in the caerphilly prospective heart disease study. , 1999, BMJ.

[26]  M. Mayr,et al.  Endothelial cytotoxicity mediated by serum antibodies to heat shock proteins of Escherichia coli and Chlamydia pneumoniae: immune reactions to heat shock proteins as a possible link between infection and atherosclerosis. , 1999, Circulation.

[27]  G. Zhong,et al.  The atherogenic effects of chlamydia are dependent on serum cholesterol and specific to Chlamydia pneumoniae. , 1999, The Journal of clinical investigation.

[28]  P. Libby,et al.  Chlamydial and human heat shock protein 60s activate human vascular endothelium, smooth muscle cells, and macrophages. , 1999, The Journal of clinical investigation.

[29]  N. Danchin,et al.  C-Reactive protein and coronary artery disease: additional evidence of the implication of an inflammatory process in acute coronary syndromes. , 1999, American heart journal.

[30]  V. Tsang,et al.  The prevalence of Chlamydia pneumoniaein atherosclerotic and nonatherosclerotic blood vessels of patients attending for redo and first time coronary artery bypass graft surgery , 1999 .

[31]  P. Libby,et al.  Chlamydial heat shock protein 60 localizes in human atheroma and regulates macrophage tumor necrosis factor-alpha and matrix metalloproteinase expression. , 1998, Circulation.

[32]  U. Mamat,et al.  Endovascular presence of viable Chlamydia pneumoniae is a common phenomenon in coronary artery disease. , 1998, Journal of the American College of Cardiology.

[33]  J. Carlquist,et al.  Infection with Chlamydia pneumoniae accelerates the development of atherosclerosis and treatment with azithromycin prevents it in a rabbit model. , 1998, Circulation.

[34]  J. Danesh,et al.  Chronic infections and coronary heart disease: is there a link? , 1997, The Lancet.

[35]  R. Schmidt,et al.  Specificity of detection of Chlamydia pneumoniae in cardiovascular atheroma: evaluation of the innocent bystander hypothesis. , 1997, The American journal of pathology.

[36]  D. Martin,et al.  In vitro infection of smooth muscle cells by Chlamydia pneumoniae , 1997, Infection and immunity.

[37]  J. Boyle,et al.  ASSOCIATION OF CORONARY PLAQUE RUPTURE AND ATHEROSCLEROTIC INFLAMMATION , 1997, The Journal of pathology.

[38]  J. Ramírez.  Isolation of Chlamydia pneumoniae from the Coronary Artery of a Patient with Coronary Atherosclerosis , 1996, Annals of Internal Medicine.

[39]  M. Leinonen,et al.  Expression of adhesion molecules on endothelial cells stimulated by Chlamydia pneumoniae. , 1996, Microbial pathogenesis.

[40]  Richard T. Lee,et al.  Macrophages and atherosclerotic plaque stability , 1996, Current opinion in lipidology.

[41]  J. Ramirez,et al.  Replication of Chlamydia pneumoniae in vitro in human macrophages, endothelial cells, and aortic artery smooth muscle cells , 1996, Infection and immunity.

[42]  M. Laakso,et al.  Association of Chlamydia pneumoniae and acute coronary heart disease events in non-insulin dependent diabetic and non-diabetic subjects in Finland. , 1996, European heart journal.

[43]  B. Davidson,et al.  Detection and widespread distribution of Chlamydia pneumoniae in the vascular system and its possible implications. , 1996, Journal of clinical pathology.

[44]  E. O’Brien,et al.  In vitro susceptibility of human vascular wall cells to infection with Chlamydia pneumoniae , 1995, Journal of clinical microbiology.

[45]  M. Puolakkainen,et al.  Further Characterization of Chlamydia pneumoniae Specific Monoclonal Antibodies , 1995, Microbiology and immunology.

[46]  D. Stewart,et al.  Detection of Chlamydia pneumoniae TWAR in human coronary atherectomy tissues. , 1995, The Journal of infectious diseases.

[47]  G. Dahlén,et al.  Lp(a) lipoprotein, IgG, IgA and IgM antibodies to Chlamydia pneumoniae and HLA class II genotype in early coronary artery disease. , 1995, Atherosclerosis.

[48]  D. Strachan,et al.  Chlamydia pneumoniae: risk factors for seropositivity and association with coronary heart disease. , 1995, The Journal of infection.

[49]  W. Beatty,et al.  Persistent chlamydiae: from cell culture to a paradigm for chlamydial pathogenesis. , 1994, Microbiological reviews.

[50]  M. Leinonen,et al.  Chlamydia pneumoniae multiplies in human endothelial cells in vitro. , 1994, Microbial pathogenesis.

[51]  D. Patton,et al.  Detection of Chlamydia pneumoniae in coronary arterial fatty streaks and atheromatous plaques. , 1992, South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde.

[52]  D. Siscovick,et al.  Association of prior infection with Chlamydia pneumoniae and angiographically demonstrated coronary artery disease. , 1992, JAMA.

[53]  M. Leinonen,et al.  Chronic Chlamydia pneumoniae Infection as a Risk Factor for Coronary Heart Disease in the Helsinki Heart Study , 1992, Annals of Internal Medicine.

[54]  M. Nieminen,et al.  SEROLOGICAL EVIDENCE OF AN ASSOCIATION OF A NOVEL CHLAMYDIA, TWAR, WITH CHRONIC CORONARY HEART DISEASE AND ACUTE MYOCARDIAL INFARCTION , 1988, The Lancet.